Appropriate use of steroids for patients with generalized Myasthenia Gravis: an international Delphi study
These findings reinforce a shift in the management of MG, advocating for the judicious and sparing use of OCS against the backdrop of expanding therapeutic options. As additional evidence-based data emerge, these recommendations should be updated.
Authors
- Nicholas J. Silvestri (ORCID: https://orcid.org/0000-0001-7931-0930)
- Pushpa Narayanaswami (ORCID: https://orcid.org/0000-0002-9412-7349)
- Francesco Saccà (ORCID: https://orcid.org/0000-0002-1323-6317)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Hiroyuki Murai (ORCID: https://orcid.org/0000-0003-1612-1440)
- Heinz Wiendl (ORCID: https://orcid.org/0000-0001-5509-1075)
Institutions
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University Medical Center Freiburg (DE)
- Federico II University Hospital (IT)
- University at Buffalo, State University of New York (US)
- International University of Health and Welfare (JP)
Publication Details
- Journal
- Therapeutic Advances in Neurological Disorders
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17562864251398375
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00